Dr. Bhawna Sirohi ne cancer ke liye **5-year national policy** ki maang ki hai. Agar genomic testing aur advanced treatments Ayushman Bharat jaise schemes ka hissa bante hain, toh diagnostic labs aur pharma companies ke liye demand ka bada blast ho sakta hai.
Healthcare mein naya trend: Precision Oncology
Ab tak hum cancer ke liye generic chemotherapy par depend karte aaye hain, lekin ab focus 'Precision Oncology' par shift ho raha hai. Iska matlab hai patient ke genetic profile ke hisaab se treatment. Dr. Bhawna Sirohi (Vedanta Medical Research Foundation) ne sarkar ko 5 saal ka ek naya national policy framework propose kiya hai taaki genomic testing ko public health schemes mein shamil kiya ja sake.
Investors ke liye kya hai game?
Isse do sector par seedha asar padne wala hai:
Diagnostic Labs: Agar genomic testing (NGS) ko govt cover karti hai, toh labs mein testing volume multi-fold badh sakta hai. Halanki, check ye karna hoga ki kya govt test prices par cap lagati hai, jisse margins par dabav aa sakta hai.
Pharma Companies: Conventional drugs se hatkar ab target therapies aur biosimilars ka zamana hai. Jo companies in high-end treatments mein lead lengi, unka market share badhna tay hai.
Challenges abhi baaki hain
Plan sunne mein toh sahi hai, lekin implementation mein 2 bade hurdles hain:
- Talent Gap: India mein trained molecular pathologists aur geneticists ki abhi bhi kami hai, jo sirf bade cities tak limited hain.
- Budget & Logistics: DIAMOnDS project jaise initiatives toh hain, par tribal aur rural areas mein in services ko pahunchana aur Ayushman Bharat ke andar in mehenge treatments ko sustain karna sarkar ke budget allocation par depend karega.
Investors ko kya track karna chahiye?
Sector par nazar rakhne wale dhyan dein:
- Kya government genomic testing ko insurance umbrella ke niche laati hai?
- Pharma companies apne oncology portfolio ko kaise adjust karti hain?
- Diagnostic labs higher volume ke sath apni profitability kaise maintain karti hain?